公开(公告)号：US20170241984A1

公开(公告)日：2017-08-24

申请号：US15438949

申请日：2017-02-22

Applicant: The Scripps Research Institute

Inventor： Corinne Lasmezas ,  Charles Weissmann

IPC: G01N33/50 ,  A61K31/454 ,  A61K31/14 ,  A61K31/351 ,  A61K31/35 ,  A61K31/4745 ,  G01N33/542 ,  A61K31/436

CPC classification number: G01N33/5023 ,  A61K31/14 ,  A61K31/35 ,  A61K31/351 ,  A61K31/436 ,  A61K31/454 ,  A61K31/4745 ,  G01N33/5041 ,  G01N33/5058 ,  G01N33/542 ,  G01N33/543 ,  G01N2500/04 ,  G01N2500/10

Abstract: A method of screening for compounds that module expression of specific macromolecules, the “target”. The method is particularly useful in that it does not require separation of target-bound and excess ligand and therefore enables, but is not limited to, High Throughput Screening for compounds that increase or decrease the levels or amounts of a target present in a biological sample. The method can also be used for high-throughput diagnosis of a condition leading to an increase or decrease of a cellular macromolecule.

公开(公告)号：US09730935B2

公开(公告)日：2017-08-15

申请号：US14567834

申请日：2014-12-11

Applicant: The Board of Trustees of the Leland Stanford Junior University

Inventor： Bingwei Lu ,  Kyu-Sun Lee

IPC: A61K31/517 ,  A61K31/35 ,  A61K31/5377 ,  C12N15/113 ,  G01N33/50

CPC classification number: A61K31/517 ,  A61K31/35 ,  A61K31/5377 ,  G01N33/5011

Abstract: Methods and compositions are provided for treating an individual having cancer. Aspects of the methods include administering to the individual an inhibitor of a non-canonical Notch signaling pathway gene in an amount effective to treat the cancer. Also provided are reagents, devices and kits thereof that find use in practicing the subject methods.

公开(公告)号：US09724328B2

公开(公告)日：2017-08-08

申请号：US14686711

申请日：2015-04-14

Applicant: NEUROTROPE BIOSCIENCE ,  THE MOUNT SINAI HOSPITAL

Inventor： Yiannis A. Ioannou ,  Lawrence Altstiel ,  David R. Crockford ,  Sathapana Kongsamut

IPC: A61K31/366 ,  A61K31/365 ,  A61K31/215 ,  A61K31/00

CPC classification number: A61K31/366 ,  A61K31/00 ,  A61K31/20 ,  A61K31/215 ,  A61K31/35 ,  A61K31/365

Abstract: Treating subjects having a lipid storage disorder with a composition comprising a PKC activator, such as bryostatins, bryologs, and polyunsaturated fatty acids.

公开(公告)号：US20170209394A1

公开(公告)日：2017-07-27

申请号：US15339346

申请日：2016-10-31

Applicant: Elcelyx Therapeutics, Inc.

Inventor： Alain D. BARON ,  Mark S. FINEMAN ,  Nigel R.A. BEELEY

IPC: A61K31/155 ,  A61K31/485 ,  A61K31/137 ,  A61K31/35 ,  A61K45/06 ,  A61K31/55

CPC classification number: A61K31/155 ,  A61K9/2086 ,  A61K9/2806 ,  A61K9/4808 ,  A61K31/137 ,  A61K31/341 ,  A61K31/35 ,  A61K31/36 ,  A61K31/381 ,  A61K31/40 ,  A61K31/4196 ,  A61K31/4453 ,  A61K31/454 ,  A61K31/485 ,  A61K31/53 ,  A61K31/55 ,  A61K45/06 ,  A61K2300/00

Abstract: Provided herein are methods for treating certain conditions, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a a biguanide or related heterocyclic compound, e.g., metformin. Also provided herein are biguanide or related heterocyclic compound compositions, and methods for the preparation thereof for use in the methods of the present invention. Also provided herein are compositions comprising metformin and salts thereof and methods of use.

公开(公告)号：US20170157160A1

公开(公告)日：2017-06-08

申请号：US15383682

申请日：2016-12-19

Applicant: ULTRAGENYX PHARMACEUTICAL INC.

Inventor： Emil KAKKIS

IPC: A61K31/7012 ,  A61K9/20 ,  A61K9/48 ,  A61K9/00

CPC classification number: A61K31/7012 ,  A61K9/0002 ,  A61K9/0053 ,  A61K9/20 ,  A61K9/2004 ,  A61K9/2009 ,  A61K9/2013 ,  A61K9/2031 ,  A61K9/205 ,  A61K9/2054 ,  A61K9/2063 ,  A61K9/48 ,  A61K9/485 ,  A61K9/4858 ,  A61K9/4866 ,  A61K31/335 ,  A61K31/35

Abstract: The present invention relates to compositions and methods for treating sialic acid deficiencies comprising extended release formulations.

公开(公告)号：US09663485B2

公开(公告)日：2017-05-30

申请号：US14442637

申请日：2013-11-14

Applicant: The United States of America, as represented by the Secretary, Dept. of Health and Human Services

Inventor： Juan Jose Marugan ,  Wei Zheng ,  Jingbo Xiao ,  John McKew

IPC: A01N43/16 ,  A61K31/355 ,  C07D311/58 ,  A61K31/335 ,  A61K31/35 ,  A61K31/352 ,  A61K31/353 ,  C07D311/72 ,  A61K31/122 ,  A61K31/724 ,  C07C50/02 ,  C07C50/06 ,  C07C50/24

CPC classification number: C07D311/58 ,  A61K31/122 ,  A61K31/335 ,  A61K31/35 ,  A61K31/352 ,  A61K31/353 ,  A61K31/355 ,  A61K31/724 ,  C07C50/02 ,  C07C50/06 ,  C07C50/24 ,  C07D311/72

Abstract: The subject invention relates to improved tocopheryl quinone derivatives and tocopherol derivatives having improved pharmacokinetics in vivo that can, in some embodiments, be useful in the treatment of Lysosomal Storage Disorders, restoration of normal mitochondrial ATP production, modulation of intracellular calcium ion concentration and other treatments or therapies. The tocopheryl quinone derivatives and tocopherol derivatives have side chains that have terminally halogenated carbon atoms.

公开(公告)号：US20170143781A1

公开(公告)日：2017-05-25

申请号：US14950407

申请日：2015-11-24

Applicant: Leslie Ann Yarborough

Inventor： Leslie Ann Yarborough

IPC: A61K36/185 ,  A61K47/46 ,  A61K35/10 ,  A61K31/202 ,  A61K31/165

CPC classification number: A61K36/185 ,  A61K9/0014 ,  A61K9/06 ,  A61K31/165 ,  A61K31/202 ,  A61K31/35 ,  A61K35/10 ,  A61K45/06 ,  A61K47/44 ,  A61K2300/00

Abstract: Natural pain relief and muscle recovery compositions having a wide variety of topical applications are provided. In certain embodiments, the pain relief composition includes moringa leaf, moringa oil, a gamma linolenic acid (GLA) source, and a capsaicin source.

公开(公告)号：US09637795B2

公开(公告)日：2017-05-02

申请号：US14001737

申请日：2012-03-16

Applicant: Sergei I. Agoulnik ,  Michael Chapman Byrne ,  Bruce A. Littlefield

Inventor： Sergei I. Agoulnik ,  Michael Chapman Byrne ,  Bruce A. Littlefield

IPC: C12Q1/68 ,  G01N33/574 ,  A61K31/35

CPC classification number: C12Q1/6886 ,  A61K31/35 ,  C12Q2600/106 ,  G01N33/57415

Abstract: The invention provides methods for predicting the efficacy of eribulin, an analog thereof, or a pharmaceutically acceptable salt thereof (e.g., eribulin mesylate), in the treatment of a subject suffering from breast cancer by determining the level of particular biomarkers in a sample derived from the subject.

公开(公告)号：US20170049793A1

公开(公告)日：2017-02-23

申请号：US14701936

申请日：2015-05-01

Applicant: Randall T. Moon ,  Travis L. Biechele ,  Nathan D. Camp ,  Stephen Haggarty ,  Daniel Fass

Inventor： Randall T. Moon ,  Travis L. Biechele ,  Nathan D. Camp ,  Stephen Haggarty ,  Daniel Fass

IPC: A61K31/708 ,  A61K31/353 ,  A61K31/7048 ,  A61K31/357 ,  A61K31/506 ,  A61K31/4406 ,  A61K31/167 ,  A61K31/196 ,  A61K31/24 ,  A61K31/4409 ,  A61K31/472 ,  A61K31/5377 ,  A61K31/69 ,  A61K31/15 ,  A61K31/495 ,  A61K31/426 ,  A61K31/52 ,  A61K31/404 ,  A61K31/405 ,  A61K31/4178 ,  A61K31/4439 ,  A61K31/047 ,  A61K31/695 ,  A61K31/407 ,  A61K31/403 ,  A61K31/421 ,  A61K31/5383 ,  A61K31/351 ,  A61K31/4152 ,  A61K31/166 ,  A61K31/585 ,  A61K31/57 ,  A61K31/565 ,  A61K31/365 ,  A61K31/201 ,  A61K31/336 ,  A61K31/4402 ,  A61K31/015 ,  A61K31/366 ,  A61K31/553 ,  A61K31/5575 ,  A61K31/55 ,  A61K31/27 ,  A61K31/4245 ,  A61K31/352

CPC classification number: A61K31/708 ,  A61K31/015 ,  A61K31/047 ,  A61K31/15 ,  A61K31/166 ,  A61K31/167 ,  A61K31/196 ,  A61K31/201 ,  A61K31/24 ,  A61K31/27 ,  A61K31/336 ,  A61K31/35 ,  A61K31/351 ,  A61K31/352 ,  A61K31/353 ,  A61K31/357 ,  A61K31/365 ,  A61K31/366 ,  A61K31/403 ,  A61K31/404 ,  A61K31/405 ,  A61K31/407 ,  A61K31/4152 ,  A61K31/4178 ,  A61K31/421 ,  A61K31/4245 ,  A61K31/426 ,  A61K31/4402 ,  A61K31/4406 ,  A61K31/4409 ,  A61K31/4439 ,  A61K31/472 ,  A61K31/495 ,  A61K31/506 ,  A61K31/52 ,  A61K31/5377 ,  A61K31/5383 ,  A61K31/55 ,  A61K31/553 ,  A61K31/5575 ,  A61K31/565 ,  A61K31/57 ,  A61K31/585 ,  A61K31/69 ,  A61K31/695 ,  A61K31/7048

Abstract: The present invention is directed toward a method of treating a subject for a condition mediated by aberrant Wnt/β-catenin signaling by selecting a subject with a condition mediated by aberrant Wnt/β-catenin signaling and administering to the selected subject a compound selected from the group consisting of those set forth in Table 1, Table 2, and a pharmaceutically acceptable salt thereof. A method of similarly modulating the Wnt/β-catenin pathway in a subject is also discussed.

Abstract translation: 本发明涉及通过选择具有由异常Wnt /β-连环蛋白信号传导介导的病症的受试者来治疗由异常Wnt /β-连环蛋白信号传导的病症的受试者的方法，并向所选择的受试者施用选自 由表1，表2所示的组及其药学上可接受的盐组成的组。 还讨论了在受试者中类似地调节Wnt /β-连环蛋白途径的方法。

公开(公告)号：US20170000762A1

公开(公告)日：2017-01-05

申请号：US15269364

申请日：2016-09-19

Applicant: SEPTEOS

Inventor： Nicolas TESSE

IPC: A61K31/352 ,  A61K31/235 ,  A61K31/045 ,  A61K31/015 ,  A61K31/11 ,  A61K31/222

CPC classification number: A61K31/352 ,  A61K9/0014 ,  A61K9/0019 ,  A61K31/015 ,  A61K31/04 ,  A61K31/045 ,  A61K31/08 ,  A61K31/11 ,  A61K31/22 ,  A61K31/222 ,  A61K31/235 ,  A61K31/35 ,  A61K31/37 ,  A61K45/06 ,  A61K47/10 ,  A61K47/32 ,  Y02A50/473 ,  A61K2300/00

Abstract: This invention pertains to an anti-microbial, in particular anti-bacterial and/or anti-fungal composition comprising cinnamaldehyde, trans-2-methoxycinnamaldehyde, cinnamyl acetate and linalool. In particular this composition is intended for preventing and/or treating microbial infection in an animal.

Abstract translation: 本发明涉及抗微生物，特别是包含肉桂醛，反式-2-甲氧基肉桂醛，肉桂酸乙酯和芳樟醇的抗菌和/或抗真菌组合物。 特别地，该组合物旨在用于预防和/或治疗动物中的微生物感染。